Biotech: Page 60
-
PharmaVoice Team/PharmaVoice
Introduction
The Pulse of the Industry By Taren Grom This first annual PharmaVOICE Year in PreVIEW is designed to provide an overview of the challenges and trends expected to impact the life-sciences industry in the coming year and beyond. For this special forum, a distinguished list of more than 100 industry...
By Taren Grom • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Business Models
Turett. The pharmaceutical industry needs to resolve multiple bipolarities: being a business and being a public utility; being doctor-focused and being consumer-focused; and being about medical innovation and being about marketing. The industry has begun a process of self-reinvention that in 2005...
By PharmaVoice Team • Jan. 2, 2008 -
Explore the Trendline➔
Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Medical Education
Medical Education Nash-Wong. Last year’s predictions on regulatory changes had us believing medical education was a thing of the past. Not so, if one considers the fact that physicians continue to attend educational meetings, despite limited food budgets and a ban on spouses. So rather than forec...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Multifunctional Teams
Multifunctional Teams Wilson. Historically, the pharmaceutical industry has faced two hurdles: achieving product registration and securing reimbursement. Today, demonstrating product value is becoming a much stronger issue. It’s not just a matter of product price, but the impact on total cost of ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Technology
Technology Cauwenbergh. Ideally, predictive tools, including assays, computer modeling techniques, and biomarkers could shorten development time, reduce the cost of development, and increase the accuracy of diagnosis, making sure that the right patient gets the right drug because of proper diagno...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Risk Management
Risk Management Turett. The term risk management implies a defensive, prepare-for-the-worst strategy. While defensive preparation is certainly important, taking a fresh look at conducting business in a “patient-first” manner will reduce the need to implement a defensive approach. In other words, ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharma POOL Matthew E. Czajkowski aaiPharma Appoints Executive VP, Chief Financial Officer Matthew E. Czajkowski has been appointed executive VP and chief financial officer of aaiPharma, Wilmington, N.C., a science-based pharmaceutical company focused on pain management. Mr. Czajkowski, 55, previ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Dr. Mark Ahn -- Poetic Science
Mark Ahn — Poetic Science For Mark Ahn, Ph.D., leadership is less about the power of one individual and more about the creation of heroic teams. Using a mix of literature, history, and traditional business skills, Dr. Ahn has found ways to unlock the imagination of his colleagues and employees at...
By Kim Ribbink • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Global Perspective
Is Japan on the Verge of a Biotech Boom? A growing number of biopharma start-up companies are looking beyond the United States and Europe for business opportunities. And one market that is generating a lot of buzz in biotech today is Japan. One of the more under-reported business stories of the p...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Biotech Drugs Will Be Hard Hit By Benefit Management Biologicals, which have received minimal pharmacoeconomic scrutiny from payers, increasingly will face the same strict value-based review and administration processes of pharmaceuticals, according to a 2005 study from The Bruckner Group Inc. (B...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Chief Risk Officers: Time for a Seat at The Table
VIEW on risk management Chief Risk Officers Time for a Seat at the Table In the wake of year one Sarbanes-Oxley compliance for U.S. public companies, there are greater challenges and increased expectations in addressing enterprise risk. Yet, compliance is not a matter of completing a one-year pro...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Drug Importation Poses Risks A federal HHS Task Force has warned in its Report on Prescription Drug Importation against the public health risks and economic effects of legalizing the importation of drugs from Canada and other countries with price controls. “This study confirms the deep flaws inhe...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
PharmaOutlet
Pharma’s Clouds Aren’t Darkening the Employee Recruitment Outlook Contributed by Julie B. Kampf Massive product safety recalls; costly accounting and pricing violations; embarrassing marketing and sales transgressions — is the beleaguered pharmaceutical sector an executive recruiter’s nightmare? ...
By Julie B. Kampf • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
On the Calendar
On the Calendar April 17-19 Medical Manufacturing Summit The Homestead Resort, Hot Springs, Va. For more information, contact Caria Badenhorst, Marcus Evans, at 246-417-5321, e-mail [email protected], or visit medicalmanufacturingsummit.com. April 18-19 Neurodegeneration in Alzheimer’s, Pa...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Making Metrics Matter -- The Changing Paradigm of R&D Metrics
Making Metrics Matter The Changing Paradigm of R&D Metrics As the pharmaceutical industry comes under greater scrutiny across the board, everything from discovery processes to R&D productivity to profit margins is subject to review. In response, top industry executives are reexamining the...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
The Asthma Market Breathes Easier
The Asthma Market Breathes Easier The approach to treating asthma continues to evolve. Rescue bronchodilator therapies are giving way, both in medical practice and in the market, to prophylactic strategies, which include inhaled corticosteroids, long-acting beta2 agonists, and leukotriene antagon...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharma POOL Dr. Mahdi B. Fawzi Dr. Frank S. Walsh Wyeth Promotes Two Research Scientists to Executive VPs Wyeth Pharmaceuticals, Madison, N.J., a division of Wyeth, has promoted Mahdi B. Fawzi, Ph.D., to executive VP, head of preclinical development, and Frank S. Walsh, Ph.D., to executive VP, he...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Medicare Part D: A Whole New Market
Medicare Part D: A Whole New Market By Kim Ribbink Marketers, manufacturers, health plans, and other stakeholders who will play a central role in the Medicare Modernization Act (MMA) are gearing up for implementation. And while there is widespread support for a change that will improve coverage t...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, marketing, And R&D Trends affecting the healthcare industry Profitable Biotech Companies Predicted to double in Next Few Years Therapeutic proteins and therapeutic antibodies collectively comprise almost 75% of biotech drugs currently on the market. Protein drugs also represent one of ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
E-Media
New electronic and web-based applications, sites, and technologies Solutions From PHT Provide Clinical Trial Savings and Flexibility Two recently launched offerings from PHT Corp., LogPad Phone and the Technology Transfer Program, aim to make the electronic capture of clinical-trial information e...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Talent Pool
executive appointments and promotions in the healthcare industry Pharma POOL Robert Boisclair Dr. Richard Bowles Steve Chellevold Mary-Frances Faraji Brent Saunders Schering-Plough Announces Senior-Level Management Changes Schering-Plough, Kenilworth, N.J., has made senior-level management change...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
The Value of Phase IV
BY Elisabeth Pena The Value of Phase IV Postmarketing research can be crucial for tracking side effects and exploring new uses for an approved drug. But these trials are heavily scrutinized because some say pharma companies have conducted such studies purely for promotional purposes with little s...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Prioritizing the Pipeline: The Critical Role of Porfolio Management
Prioritizing the Pipeline The critical role of portfolio management Increased pressures on the pharmaceutical industry – shrinking pipelines, rising costs, reimbursement issues, regulatory pressures, and consumer demands – mean companies have to find ways to focus on the projects that will meet c...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Talent Pool
talent pool executive appointments and promotions in the healthcare industry Pharma POOL Robert Bertolini Schering-Plough Appoints Executive VP, Chief Financial Officer Schering-Plough has appointed Robert J. Bertolini as executive VP and chief financial officer. He also serves on the Schering-Pl...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
On the Calendar
January 10-11 Clarifying the Regulatory Framework of Pharmaceutical Marketing Philadelphia For more information, contact Anne Marie Coluccio, PTi international, at 212-661-3500 ext. 3229, e-mail [email protected], or visit pti-international.com. January 24-25 Manage the Cost of Spec...
By PharmaVoice Team • Jan. 2, 2008
Previous
